179 related articles for article (PubMed ID: 35708257)
21. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
[TBL] [Abstract][Full Text] [Related]
22. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
[TBL] [Abstract][Full Text] [Related]
23. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
[TBL] [Abstract][Full Text] [Related]
26. Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
Armstrong AW; Fitzgerald T; McLean RR; Teeple A; Uy JP; Olurinde M; Rowland K; Guo L; Shan Y; Callis Duffin K
Dermatol Ther (Heidelb); 2023 Feb; 13(2):629-640. PubMed ID: 36585606
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
Zhuang JY; Li JS; Zhong YQ; Zhang FF; Li XZ; Su H; Zhang ZQ; Wang XH; Chen YF
Dermatol Ther; 2021 Sep; 34(5):e15054. PubMed ID: 34228392
[TBL] [Abstract][Full Text] [Related]
28. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
Ruggiero A; Fabbrocini G; Cinelli E; Megna M
Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China.
Yang J; Hu K; Li X; Hu J; Tan M; Zhang M; Kuang Y; Lv C; Chen J
Dermatol Ther (Heidelb); 2023 Feb; 13(2):477-485. PubMed ID: 36481840
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
Nemoto O; Hirose K; Shibata S; Li K; Kubo H
Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
[TBL] [Abstract][Full Text] [Related]
31. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis.
Michelucci A; Manzo Margiotta F; Panduri S; Tonini A; Romanelli M; Morganti R; Janowska A; Dini V
Dermatol Ther; 2022 Apr; 35(4):e15339. PubMed ID: 35088508
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry.
Hugo J; Kojanova M; Turkova B; Gkalpakiotis S;
Dermatol Ther (Heidelb); 2023 Mar; 13(3):787-801. PubMed ID: 36723775
[TBL] [Abstract][Full Text] [Related]
34. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
36. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
[TBL] [Abstract][Full Text] [Related]
37. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
Teeple A; Fitzgerald T
J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
[TBL] [Abstract][Full Text] [Related]
38. Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate-to-severe plaque psoriasis: the COMPASS analysis.
Diels J; Thilakarathne P; Cameron C; McElligott S; Schubert A; Puig L
Br J Dermatol; 2020 Aug; 183(2):276-284. PubMed ID: 31652347
[TBL] [Abstract][Full Text] [Related]
39. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
[TBL] [Abstract][Full Text] [Related]
40. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
